Henry Schein has been outperforming the S&P 500 since December 2024. Check out the price action, momentum, volume, and ...

Highlights,Charles Schwab Investment Management increased its holdings in Henry Schein, reaching close to 1% ...

The stock's fall snapped a four-day winning streak.

Learn more about whether Henry Schein, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...

Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, ...

Discover Henry Schein's impressive 2024 financial performance, with nearly $13 billion in net sales and a 5.8% increase in fourth quarter sales.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Henry Schein (HSIC – Research Report) today and set a price target of ...

NasdaqGS:HSIC Earnings and Revenue History March 5th 2025 The Impact Of Unusual Items On Profit. For anyone who wants to understand Henry Schein's profit beyond the statutory numb ...

Dental and medical products company Henry Schein (NASDAQ:HSIC) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 5.8% year on year to $3.19 billion. Its non-GAAP profit of $1.19 ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...